Kalaris Therapeutics (KLRS) Company Report

Kalaris Therapeutics, Inc. announced an oversubscribed private placement to raise approximately $50.0 million in aggregate gross proceeds.
The company is selling 4,200,000 shares of common stock at $10.00 per share and pre-funded warrants to purchase 800,000 shares at $9.9999 per pre-funded warrant.
The private placement is expected to close on or about December 19, 2025.
Kalaris anticipates that the net proceeds, combined with existing cash, will fund operations into the third quarter of 2027.
The proceeds will be used to advance the clinical development of TH103 for neovascular AMD and for general corporate purposes.

Dec 18, 2025, 12:29 PM

Kalaris Therapeutics Announces $50.0 Million Private Placement

KLRS

New Projects/Investments

Guidance Update

Kalaris Therapeutics (KLRS) has entered into a securities purchase agreement for a private placement, expecting to raise approximately $50.0 million in gross proceeds.
The private placement includes the sale of 4,200,000 shares of common stock at $10.00 per share and 800,000 pre-funded warrants at $9.9999 per warrant.
The company anticipates that its existing cash, cash equivalents, short-term investments, and the net proceeds from this private placement will fund operations into the third quarter of 2027.
The proceeds will be used to advance the clinical development of TH103 for neovascular AMD and for general corporate purposes.

Dec 17, 2025, 10:59 PM

Kalaris Therapeutics Reports Initial Positive Phase 1a Data for TH103

KLRS

Kalaris Therapeutics, Inc. announced positive initial data from its Phase 1a single ascending dose (SAD) trial of TH103 for treatment-naïve neovascular age-related macular degeneration (nAMD) on December 17, 2025.
The data demonstrated clinically meaningful improvements in vision and retinal anatomy, including a mean 10-letter gain in visual acuity and a mean 129 µm improvement in central subfield thickness at Month 1.
TH103 was generally well tolerated, with no dose-limiting toxicities or TH103-related serious adverse events observed, and an updated manufacturing process successfully addressed initial instances of intraocular inflammation.
Pharmacokinetic analysis indicated 27 to 51-fold lower plasma Cmax compared to current leading anti-VEGF agents, consistent with enhanced intraocular retention, and 31% of patients required no additional anti-VEGF treatment for six months after a single TH103 injection, suggesting potential for extended durability.
Kalaris is accelerating enrollment in its ongoing Phase 1b/2 multi-ascending dose-finding study, with preliminary efficacy and safety data expected in the second half of 2026.

Dec 17, 2025, 10:19 PM

Kalaris Therapeutics Reports Q3 2025 Financial Results and Provides Business Updates

KLRS

Earnings

Guidance Update

CFO Change

Kalaris Therapeutics reported a net loss of $11.9 million for the third quarter ended September 30, 2025, compared to a net loss of $38.1 million for the same period in 2024.
As of September 30, 2025, the company held $77.0 million in cash, cash equivalents, and short-term investments, which is expected to fund operations into 2027.
Initial clinical data from the Phase 1a Single Ascending Dose trial for TH103 is anticipated by year-end 2025, while the Phase 1b/2 Multiple Ascending Dose trial is currently enrolling, with initial data expected in 2H 2026.
Recent corporate milestones include the selection of KBI Biopharma as the Contract Development and Manufacturing Organization (CDMO) for TH103 and the appointment of Matthew Gall as Chief Financial Officer.

Nov 12, 2025, 1:13 PM

Get instant answers from SEC filings, earnings calls & more

Kalaris Therapeutics (KLRS)